Trumps 10 Billion IRS Lawsuit Dropped After DOJ Agrees to Create 18 Billion Lawfare Compensation Fund Cavaliers Face Financial Restraints in Potential James Harden Contract Negotiations NASA Taps Blue Origin for First of Three Uncrewed Lunar Missions as 20 Billion Moon Base Plans Take Shape MarketSmith India Highlights Stock Picks for May 26 Session Were Expanding the Cinematic Toolbox AI Fault Lines on Show at Cannes Inflation Pressures Widen Beyond Oil and Iran Other Sectors Show Reacceleration Essent Group Q1 2026 Earnings Strong EPS Beat Amid Mixed Market Sentiment LMND Q1 2026 Earnings Narrowing Losses Beat Expectations as Underwriting Improves MSGE Q1 2026 Earnings EPS Falls Short of Estimates Stock Edges Higher OneSpan Q1 2026 Earnings EPS Beat Drives 234 Stock Gain Amid Solid Execution NewAmsterdam Pharma NAMS Q1 2026 Earnings Narrowerthanexpected loss as biotech advances pipeline SBC Q1 2026 Earnings EPS Exceeds Estimates as Stock Dips Despite Strong Profitability United States Antimony UAMY Surges 348 as Critical Mineral Demand Intensifies RILYZ Bonds Edge Higher Amid Steady Market Activity Cardlytics CDLX Edges Higher Analyzing the Recent Uptick and Key Technical Levels Adagene ADAG Edges Lower Amid Quiet Trading Holds Above Key Support Primo Brands Corporation PRMB Holds Near 2453 as Support and Resistance Levels Tighten Anthropic and Microsoft in Talks for AI Chip Deal Following 5 Billion Investment Archrock Inc AROC Q1 2026 Earnings EPS Misses Estimates as Stock Declines Chubb Limited CB Edges Lower Amid Broader Market Caution Potential Support Levels in Focus PHVS Q1 2026 Earnings NarrowerThanExpected Loss as Biotech Advances HAE Pipeline Bowman Consulting Group Ltd BWMN Q1 2026 Earnings EPS Falls Sharply Short of Estimates Amid Challenging Quarter SPOT Q1 2026 Earnings EPS Surges Past Estimates Stock Jumps 6 DCOMP Q1 2026 Earnings Preferred Stock EPS Misses Estimates Upstream Bio UPB Q1 2026 Earnings NarrowerThanExpected Loss Amid No Revenue Stock Edges Lower RILYP Q1 2024 Earnings Preferred Stock Reports Negative EPS Amid No Revenue Estimate Marker Therapeutics Inc MRKR Q1 2026 Earnings EPS Beat Expectations Amid Development Stage Operations